Dendreon Corporation Announces Filing of Shelf Registration Statement.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Jan. 6, 2003 Dendreon Corporation (Nasdaq:DNDN) today announced that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC) that, upon being declared effective by the SEC, will allow Dendreon to sell from time to time up to $75 million of common stock. The nature and terms of any offering will be established at the time of sale. Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. Dendreon currently has multiple therapeutic vaccines therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. in clinical trials and preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development. Dendreon's product pipeline also includes monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and a pathway to small molecules. Dendreon has established important alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. Copies of the preliminary prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders included in the registration statement may be obtained from Investor Relations Investor relations The process by which the corporation communicates with its investors. , care of Dendreon Corporation, 3005 First Avenue, Seattle, WA 98121. The shelf registration statement relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the common stock has been filed with the SEC but has not yet become effective. The common stock may not be sold, nor may offers to buy the common stock be accepted prior to the time the shelf registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation solicitation In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual of an offer to buy, nor shall there by any sale of the common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state. Except for historical information contained herein, this news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of offering common stock under the shelf registration statement as well as in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Dendreon may be unable to sell common stock under the shelf registration statement for a number of reasons, including market conditions, developments affecting its business, negative investor sentiment toward biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. in general, or Dendreon's being unable to satisfy any applicable selling conditions required by particular investors. Factors that may affect Dendreon's ability to discover, develop and commercialize drugs that are safe and effective for use as human therapeutics include risks related to the uncertainty of Dendreon's future access to capital, Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the Food and Drug Administration will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion